Literature DB >> 20002967

MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis.

Vasiliki Zouvelou1, Michael Rentzos, Panagiotis Toulas, Ioannis Evdokimidis.   

Abstract

Muscle atrophy, particularly of facial and bulbar muscles, seems to be a relatively common long-term consequence of musclespecific tyrosine kinase-myasthenia gravis (MuSK-MG), perhaps reflecting the chronic state of disease or long-term therapy with corticosteroids. We performed magnetic resonance imaging (MRI) to assess muscle wasting in the facial and bulbar muscles in two female MuSK-MG patients, with short duration of symptoms prior to diagnosis and prior to commencement of steroid therapy. The study revealed marked atrophy of temporalis, masseters, and lingual muscles with fatty replacement. MRI evidence of early muscle atrophy in MuSK-MG may indicate that MuSK antibodies per se may predispose to muscle atrophy.
© 2009 by the American Society of Neuroimaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002967     DOI: 10.1111/j.1552-6569.2009.00456.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  4 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  When myasthenia gravis is not all.

Authors:  V Damato; P E Alboini; A Mastrorosa; A Dickmann; C Colosimo; A Evoli
Journal:  J Neurol       Date:  2014-03-15       Impact factor: 4.849

3.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

4.  MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis.

Authors:  Georgios Velonakis; Vassilis E Papadopoulos; Efstratios Karavasilis; Dimitrios K Filippiadis; Vasiliki Zouvelou
Journal:  Neuroradiology       Date:  2021-07-07       Impact factor: 2.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.